|
|
||||||||
Ann Thorac Surg 2003;76:1843-1848
© 2003 The Society of Thoracic Surgeons
a Department of Thoracic and Cardiovascular Surgery, Jean-Minjoz Hospital, Besançon, France
b Department of Biostatistics, University Hospital, Dijon, France
Accepted for publication June 3, 2003.
* Address reprint requests to Dr Falcoz, Department of Thoracic and Cardiovascular Surgery, Hôpital Jean-Minjoz, Boulevard Fleming, 25000 Besançon, France
e-mail: pierre-emmanuel.falcoz{at}wanadoo.fr
| Abstract |
|---|
|
|
|---|
METHODS: The authors propose a decision analytic model including a cost-effectiveness study to compare two clinical strategies: VATS (reference strategy) and conservative management (alternative strategy). Data were obtained from a Medline search for English language articles and cost estimates were derived from the financial and public health departments of our hospital. The model was analyzed to determine the baseline strategy leading to the highest expected effectiveness and the lowest expected cost.
RESULTS: Conservative management offered a slight advantage in expected effectiveness value (99.99 vs 99.93 for VATS). VATS produced the lowest expected cost (
4347 vs
7536 for conservative management). The incremental cost-effectiveness ratio was
57,750. Within the ranges tested, the sensitivity analysis presented consistent results in terms of effectiveness and advocated conservative management as the best strategy. In terms of cost, with the exception of length of stay, the sensitivity analysis was insensitive in estimating the different probabilities, and favored VATS over conservative management.
CONCLUSIONS: In the management of the second episode of spontaneous pneumothorax, VATS offers substantial savings in cost for only a slight decrease in effectiveness, when compared with conservative management.
| Introduction |
|---|
|
|
|---|
Conservative management (CM) has long been the generally accepted treatment strategy for the second episode of SP (pleural drainage and a "wait and see" approach) [1, 2]. Thanks to advances in thoracoscopic instrumentation (such as optics, instruments, and endoscopic staplers) treatment strategy has progressively changed since the early 1990s, and video-assisted thoracic surgery (VATS) has set a new standard of excellence for treating the second episode of SP [35].
Nevertheless, there is still controversy as to what the best strategy is for a patient presenting a second episode of SP. The answer to this question remains unclear due to the lack of controlled clinical trials comparing the two possible treatment strategies. We propose a decision analytic model to examine this clinically important issue.
The aim of this study was to compare two possible treatment strategies, VATS and CM, in order to assess which of the two was better adapted for the treatment of the second episode of SP.
| Material and methods |
|---|
|
|
|---|
|
|
The financial impact of the management of the second episode of SP may be considered from different perspectives, for example: the physician's time or health-care costs. Our model looks at financial impact from the national health insurance perspective. Because it was not possible to determine real costs, only direct costs were taken into account. No attempt was made to include noninstitutional costs, either direct or indirect, born by the patients and their families or by society.
Assumptions
In designing the decision tree, several assumptions were made in order to simplify the analysis. Complications that followed an episode of SP were categorized into three groups, regardless of the chosen treatment strategy: short-term (less than 1 month), medium-term (less than 3 months), and long-term (less than 2 years). All potential complications were considered either as imperfect results or major complications. Imperfect results were: minor air leak, pleural effusion, incomplete reexpansion of the lung (failing pleurodesis), and short-term ipsilateral recurrent pneumothorax. Major complications were: hemothorax or pleural infection following surgery or chest tube insertion, prolonged air leak, and middle- and long-term ipsilateral recurrent pneumothorax. For each VATS, the probability of conversion to thoracotomy was taken into account.
Utility and probabilities of chance events
The concept of utility is a measure of a decision maker's relative preference for an outcome state. Each of the health states at the terminal nodes of the decision tree, which represent the final outcomes, are thus assigned a utility value that quantifies preferences for these states [7]. In the context of the present decision tree, the final outcomes under study were either definitive resolution or ensuing complications. They were estimated over a 2-year period because most recurrences occur during the first 2 years after the initial pneumothorax [8]. The utility of a patient having a definitive resolution, which is the optimal outcome, was assigned a value of 100. The utility of a patient experiencing a course with ensuing complications was assigned a value of 0.
Table 1 summarizes the main data probabilities and estimates of their values used in the decision analysis. These values are based on a critical review of the available literature regarding SP management. We performed a systematic Medline search for all English language articles dating from 1966 and falling under the medical subject headings "spontaneous pneumothorax," "pleural drainage," "thoracoscopy," and "video-assisted thoracic surgery" alone and in combination with the terms "randomized controlled trials," "meta-analysis," and "guidelines." This survey of the medical literature was done to obtain a baseline value and a range for all variables of interest. Decision tree values were assigned by applying critical appraisal criteria (methodologic quality, largest number of cases reported, most recent information, and relevance to our study population) in the articles retrieved [9].
Cost data
Costs, expressed in euros (
), were provided by the financial department of our hospital. They are those of the actual procedures for pneumothorax. The total cost of both surgical and anesthetic procedures was taken into account. The anesthetic cost was
188.1 for VATS and thoracotomy, and
20.9 for CM. The surgical cost was
418 for VATS and thoracotomy, and
41.8 for CM. The cost per day of hospitalization was
584.19 (ranging from
416.93 to
724.03).
The public health department provided the mean and standard deviation of length of stay over a 5-year period (1998 to 2002) of 133 patients suffering a second episode of SP: 5.4 ± 1.8 days for VATS (n = 82 patients), 10.5 ± 3.5 days for thoracotomy (n = 17 patients), and 9.4 ± 6.9 days for CM (n = 34 patients).
Sensitivity analysis
The stability of the results obtained from the model for mean probabilities and costs was assessed through sensitivity analysis. Sensitivity analysis is a method of varying probabilities over a defined range to determine how the optimal choice would change if the value of a chance event changed [10].[1124] Sensitivity analysis can be performed on individual probabilities (one-way sensitivity analysis) or by varying two probabilities at the same time (two-way sensitivity analysis). One-way sensitivity analysis was performed for each probability in the decision tree, and the value at which the optimal strategy changed (threshold value) was identified. Two-way sensitivity analysis was performed for all probabilities found to be relevant in one-way sensitivity analysis.
| Results |
|---|
|
|
|---|
|
The strategy producing the lowest expected cost was VATS. The cost-effectiveness ratio for one recovery was
44 for VATS and
75 for CM. The incremental cost-effectiveness ratio was
57,750 for CM, which means that the cost of one additional recovery by CM, when compared to VATS, was
57,750.
Sensitivity analysis
Because the probabilities for the various outcomes used in this analysis could conceivably vary, sensitivity testing was performed to assess the validity of the conclusions over a wide range of probabilities.
In terms of effectiveness, the sensitivity analysis demonstrated consistent results and advocated CM as the better of the two strategies regardless of the probability concerned. Within the ranges tested, the different variables in the model influenced the weight of VATS, but did not change the preferred strategy. Examples are given in Figure 2, which illustrates the effect of definitive resolution after VATS (Fig 2A) and the effect of definitive resolution after CM (Fig 2B) on the two management strategies.
|
|
| Comment |
|---|
|
|
|---|
The use of decision analysis in surgery is gaining interest [28, 29]. In a complex decision-making environment, where medical practice is influenced by published clinical trials, consensus statements and detailed formal examination of procedures, physicians may perform inadequately in establishing the standard of care if they rely only on their clinical judgment based uniquely on past experience. Since none of us can intuitively estimate probabilities accurately, decision analysis becomes useful when it is desirable to compare alternative treatment strategies quantitatively. Nevertheless, this method has its own limitations. Some of the limitations of our decision analysis imposed by the assumptions and tree structure deserve mention. First, the possibility of having to perform a thoracotomy was taken into account. We decided not to exclude this option from our model in order to leave the surgeon the choice of which technique he judged the more appropriate to treat a major complication (eg, hemothorax). Second, we used estimated costs of the actual procedures for SP to compare the cost of the two strategies. The ideal approach would have been to look at the real cost of each procedure and model those costs explicitly. Such a cost analysis was beyond the scope of the current work and not really justified in a comparative study.
Despite the above limitations from the standpoint of baseline probabilities, our analysis reveals only a slight advantage in terms of expected effectiveness for CM. The difference we take into account in our analysis between CM and VATS (incremental effectiveness value of 0.06) may be somewhat disturbing to readers. This value is rather small and, consequently, the difference between the two strategies is only slight. However, from the perspective of decision analysis, it is not the quantity but the sense of the difference between two treatment strategies that guides the choice of the decision [6]. It is especially noteworthy that sensitivity analysis did not have a significant impact on the baseline results. In the absence of variation in the sensitivity analysis, the interpretation of results can be considered reliable and robust. In addition, although the primary goal of this study was to compare two possible treatment strategies, VATS and CM, in the management of a second episode of SP, the present model also provides information for a hierarchical choice between VATS and thoracotomy, keeping in mind that thoracotomy is often reserved for patients with technically more complex problems. Be that as it may, VATS would have provided 95 additional recoveries for 10,000 patients undergoing surgery for a second episode of SP. Hence, it should be considered whenever surgery is necessary. This finding has already been reported in many studies dealing with VATS versus thoracotomy for SP [19, 24, 27], especially in primary SP [25].
In the present study, VATS was the strategy found to produce the lowest expected cost. This result was principally due to a shorter "cost-consuming" length of stay. Schramel and colleagues [30] highlighted this in a cost analysis study comparing VATS and CM. The length of stay for VATS was 5.4 ± 1.8 days in our study, 6.9 days (ranging from 2 to 15 days) in Crisci and Coloni's study [31], whereas it was 11 ± 4 days in Schramel associates' study [30] and 2.9 ± 0.9 in Hazelrigg and coworkers' study [32]. In considering the discordance in the length of stay between these studies (postoperative length of stay for European patients is typically much longer than for US patients) it was necessary to examine the impact on the results of these variations in duration. By varying the length of stay for CM, the one-way sensitivity analysis revealed that the threshold value at which outcomes were equivalent was 4.9 days. CM should be preferred below this threshold value, and VATS above it. The two-way sensitivity analysis indicates the preferred strategy in function of the mean length of stay (Fig 3). The shorter the length of stay for VATS, the smaller the area in which CM was the optimal strategy. Therefore, depending on the length of stay in a given institution, the clinician may well choose one strategy or the other.
Cost effectiveness is becoming more and more important in the choice of treatment. The incremental cost-effectiveness ratio found in our study was approximately
58,000 for CM. Deciding whether a strategy is cost effective is a subjective interpretation of the cost-effectiveness ratio. Although there is no absolute cutoff level, there is a consensus that a cost-effectiveness ratio under the accepted limit of
50,000 corresponds to a cost-effective strategy [33]. Hence, CM is definitely not cost effective for the management of the second episode of SP in our study.
In conclusion, the results we obtained using decision analysis for the management of the second episode of SP reveal that VATS offers substantial savings in cost for only a slight decrease in effectiveness when compared with CM. Institutions whose probabilities reflect those presented in our analysis may well want to consider performing VATS in all patients undergoing a second episode of SP. Nevertheless, further clinical trials should help to validate the formal analytic results found in this study.
| Acknowledgments |
|---|
|
|
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
C. Casali, A. Stefani, G. Ligabue, P. Natali, B. Aramini, P. Torricelli, and U. Morandi Role of Blebs and Bullae Detected by High-Resolution Computed Tomography and Recurrent Spontaneous Pneumothorax Ann. Thorac. Surg., January 1, 2013; 95(1): 249 - 255. [Abstract] [Full Text] [PDF] |
||||
![]() |
J-M. Tschopp, R. Rami-Porta, M. Noppen, and P. Astoul Management of spontaneous pneumothorax: state of the art. Eur. Respir. J., September 1, 2006; 28(3): 637 - 650. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |